Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Bernstein

Showing results (291-300 of 300) with videos related to

Pageof 30
Sort By:
You have reached the last page of results.This site can display upto 300 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2003
Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summaryRichard Gorlick, Peter Anderson, Irene Andrulis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2014
Toward a drug development path that targets metastatic progression in osteosarcomaChand Khanna, Timothy M Fan, Richard Gorlick, et al.
Nature|July 10, 2024
Single-cell atlas of the human brain vasculature across development, adulthood and diseaseThomas Wälchli, Moheb Ghobrial, Marc Schwab, et al.
Nature|August 31, 2017
Fate mapping of human glioblastoma reveals an invariant stem cell hierarchyXiaoyang Lan, David J Jörg, Florence M G Cavalli, et al.
Nature Cancer|February 5, 2022
Gradient of Developmental and Injury Response transcriptional states defines functional vulnerabilities underpinning glioblastoma heterogeneityLaura M Richards, Owen K N Whitley, Graham MacLeod, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2015
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled TrialStefan S Bielack, Sigbjørn Smeland, Jeremy S Whelan, et al.
European Journal of Cancer (Oxford, England : 1990)|January 28, 2019
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohortSigbjørn Smeland, Stefan S Bielack, Jeremy Whelan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2019
Functional Repair Assay for the Diagnosis of Constitutional Mismatch Repair Deficiency From Non-Neoplastic TissueAndrew Y Shuen, Stella Lanni, Gagan B Panigrahi, et al.
Nature Communications|February 13, 2021
PRMT5 inhibition disrupts splicing and stemness in glioblastomaPatty Sachamitr, Jolene C Ho, Felipe E Ciamponi, et al.
The Lancet. Oncology|August 30, 2016
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trialNeyssa M Marina, Sigbjørn Smeland, Stefan S Bielack, et al.
Pageof 30

Showing results (291-300 of 300) with videos related to

Sort By:
Pageof 30
You have reached the last page of results.This site can display upto 300 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2003
Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summaryRichard Gorlick, Peter Anderson, Irene Andrulis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2014
Toward a drug development path that targets metastatic progression in osteosarcomaChand Khanna, Timothy M Fan, Richard Gorlick, et al.
Nature|July 10, 2024
Single-cell atlas of the human brain vasculature across development, adulthood and diseaseThomas Wälchli, Moheb Ghobrial, Marc Schwab, et al.
Nature|August 31, 2017
Fate mapping of human glioblastoma reveals an invariant stem cell hierarchyXiaoyang Lan, David J Jörg, Florence M G Cavalli, et al.
Nature Cancer|February 5, 2022
Gradient of Developmental and Injury Response transcriptional states defines functional vulnerabilities underpinning glioblastoma heterogeneityLaura M Richards, Owen K N Whitley, Graham MacLeod, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2015
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled TrialStefan S Bielack, Sigbjørn Smeland, Jeremy S Whelan, et al.
European Journal of Cancer (Oxford, England : 1990)|January 28, 2019
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohortSigbjørn Smeland, Stefan S Bielack, Jeremy Whelan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2019
Functional Repair Assay for the Diagnosis of Constitutional Mismatch Repair Deficiency From Non-Neoplastic TissueAndrew Y Shuen, Stella Lanni, Gagan B Panigrahi, et al.
Nature Communications|February 13, 2021
PRMT5 inhibition disrupts splicing and stemness in glioblastomaPatty Sachamitr, Jolene C Ho, Felipe E Ciamponi, et al.
The Lancet. Oncology|August 30, 2016
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trialNeyssa M Marina, Sigbjørn Smeland, Stefan S Bielack, et al.
Pageof 30